title: Dyslipidaemia: cardiovascular prevention--end of the road for niacin?
abstract: The recently published HPS2–THRIVE study has shown that the addition of extended release niacin to statin therapy in patients with well-controlled levels of LDL cholesterol does not reduce the risk of cardiovascular events and might even increase harm. Consequently, the use of niacin to increase levels of HDL cholesterol is not recommended.
authors.affiliation: Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 11-125 Smilow Centre for Translational Research, 3400 Civic Centre Blvd, Philadelphia, PA 19104, USA.
authors.forename: Sony
authors.initials: S
authors.lastname: Tuteja
authors.affiliation: Department of Genetics, Perelman School of Medicine, University of Pennsylvania, 11-125 Smilow Centre for Translational Research, 3400 Civic Centre Blvd, Philadelphia, PA 19104, USA.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Rader
mesh_terms: D002318:Cardiovascular Diseases / Q000517:prevention & control*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D009525:Niacin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D009525:Niacin